Navigation Links
iTherX Initiates Phase 1b Study of First-in-Class Hepatitis C Virus Entry Inhibitor ITX-5061
Date:3/15/2011

SAN DIEGO, March 15, 2011 /PRNewswire/ -- iTherX, a pharmaceutical company dedicated to discovering and developing a new class of therapies for hepatitis C, today announced that it has commenced patient recruitment in an open-label, proof-of-concept Phase 1b study of its lead compound ITX-5061 in liver transplant patients with hepatitis C virus infection (HCV).  ITX-5061 represents a first-in-class compound that inhibits entry of the hepatitis C virus into liver cells.

"ITX-5061 possesses a unique mechanism of action that prevents the hepatitis C virus from entering liver cells and has demonstrated potent preclinical antiviral activity against all HCV genotypes.In addition, it has already demonstrated safety in more than 280 subjects," said Jeffrey McKelvy, PhD, MD, President and Chief Executive Officer of iTherX.  "We hope ITX-5061 will significantly improve long-term transplant outcomes."

The primary objective of the Phase 1b clinical trial will be to assess the safety and tolerability of ITX-5061 in liver transplant patients.  The study will also assess HCV viral load for three months after liver transplantation to determine if ITX-5061 has any immediate and/or sustained impact on viral kinetics in treated patients. Approximately 20 patients will be enrolled into one of two cohorts:  one group will receive supportive care only, while the second cohort will also receive ITX-5061 at a150 mg daily dose for seven days.  The trial is being conducted at the University of Birmingham, UK under the direction of David Mutimer, MBBS, MD, FRACP, FRCP, Reader in Hepatology at Birmingham University and Consultant Hepatologist to the Birmingham QE Hospital Liver and Hepatobiliary Unit.

Preclinical studies have shown ITX-5061 to be a potent and selective inhibitor of HCV entry into hepatocytes, capable of preventing virus binding/fusion and cell to cell spread, suggesting ITX-5061  may reduce re-infection rates followi
'/>"/>

SOURCE iTherX
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
2. Conatus Pharmaceuticals Initiates Confirmatory Phase 2 Clinical Trial of CTS-1027 for the Treatment of Hepatitis C Virus (HCV)
3. New Mexico Software Initiates Medical Second Opinion Service via Telemedicine for Remote Consultation Review
4. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
5. Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
6. American Regent Initiates Nationwide Voluntary Recall of Potassium Phosphates Injection, USP, 15 mM/5 mL Phosphorus; 22 mEq/5 mL Potassium, 5 mL Single Dose Vial, Lot # 0048 Due to Translucent Visible Particles
7. American Regent Initiates Nationwide Voluntary Recall of Sodium Thiosulfate Injection, USP
8. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
9. Zacks Investment Research Initiates Coverage on Viral Genetics
10. ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
11. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2014)... 2014 /PRNewswire-iReach/ -- This is a professional ... Chinese Vardenafil (CAS 224785-90-4) industry. The report ... (CAS 224785-90-4) including its classification, application and ... and China,s top manufacturers of Vardenafil (CAS ... value, cost, gross margin and market share ...
(Date:7/25/2014)... 25, 2014  Depomed, Inc. (NASDAQ: DEPO ... fiscal year 2014 financial results after the market closes ... conference call beginning at 4:30 pm EDT, 1:30 pm PDT to ... call by dialing 877-317-6789 ( United States ... be available via a live webcast on the investor ...
(Date:7/25/2014)... July 25, 2014  CVS Caremark Corporation (NYSE: ... on Tuesday, August 5, 2014, at 8:30 a.m. (EDT) ... 2014 financial results. An audio webcast of ... Investor Relations portion of the CVS Caremark website for ... http://info.cvscaremark.com/investors . This webcast will be archived and available ...
Breaking Medicine Technology:Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 2Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 3Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 4Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2
... gamma imaging,(BSGI) is effective in the detection of cancers ... a study presented today at the annual meeting of,the ... "BSGI can identify the most ... Rachel F. Brem, M.D., professor of,radiology and director of ...
... Laboratories, a leading clinical-diagnostics and biomedical-research laboratory specializing ... launched two tests to evaluate the response ... to a primary immunodeficiency disorder, chemotherapy drugs, or because ... a transplant. The company launched the two new assays, ...
Cached Medicine Technology:New Breast Imaging Technology Targets Hard-to-Detect Cancers 2New Breast Imaging Technology Targets Hard-to-Detect Cancers 3IBT Laboratories Expands its Menu of Tests for Immune Deficiency 2
(Date:7/28/2014)... parents access to a website containing information about the ... cost-effective way of increasing its uptake, new University of ... vaccine via a website containing information helping parents make ... per vaccination to the NHS than informing them solely ... a leaflet providing information about the vaccine. In each ...
(Date:7/28/2014)... July 28, 2014 According to the Greek ... is a comprehensive fitness guide that teaches men how to ... , Vkool reveals in its review that inside the ... Ways to gain the maximum muscle fiber ... build muscle and avoid fat gain , Ways ...
(Date:7/28/2014)... July 28, 2014 CW4K was among ... Lady Michelle Obama and Partnership for a Healthier ... they join the group's DrinkUP effort, which ... more often. , The seven organizations added included ... Outdoor Products, S’well Bottle, Santa Clara Valley Water District ...
(Date:7/28/2014)... DC (PRWEB) July 28, 2014 As ... many are looking to private exchanges. “Private Exchange ... August 6 webinar from Atlantic Information Services, will provide ... private exchange strategies for the future. , Barbara Gniewek, ... PwC with extensive experience in the private exchange sector ...
(Date:7/28/2014)... According to the Heartburn No More PDF review recently ... help people get rid of acid reflux naturally. ... heartburn and acid reflux. In addition, inside this book, people ... factors for reflux disease. , Vkool informs in its ... symptoms of reflux disease naturally without medications. The book also ...
Breaking Medicine News(10 mins):Health News:Online information most cost-effective means of increasing MMR uptake, research finds 2Health News:Greek God Muscle Building Program Review Exposes Greg O’Gallagher's Muscle Building Guide for Men – Vkool.com 2Health News:Greek God Muscle Building Program Review Exposes Greg O’Gallagher's Muscle Building Guide for Men – Vkool.com 3Health News:CannedWater4Kids (CW4K) Among Those Invited to the White House to Support First Lady Michelle Obama in Welcoming Seven New Organizations to DrinkUP 2Health News:CannedWater4Kids (CW4K) Among Those Invited to the White House to Support First Lady Michelle Obama in Welcoming Seven New Organizations to DrinkUP 3Health News:Three PwC Consultants to Offer Insurers Successful Strategies for Private Exchanges 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 3
... Improving communications skills and the use of a simple ... inappropriate prescriptions of antibiotics, a joint Cardiff University trial ... trial, published in the British Medical Journal , ... Medicine together with researchers from the Maastricht University Medical ...
... Tartrate Sublingual Tablet in Treating Middle-of-the-Night Awakening ... in the Treatment of Obsessive Compulsive DisorderRICHMOND, ... (Nasdaq: TSPT ), a specialty ... commercialization of proprietary products that address important ...
... laser-assisted liposuction offers patients better results and quicker ... liposuction systems currently on the market; Now available ... 21 Palomar Medical Technologies, Inc. (Nasdaq: ... of light-based systems for cosmetic treatments, announced today ...
... Inc. (MDLH. PK) ( http://www.mitcanada.ca http://www.mitinvest.ca ), ... the Joint Venture Agreement with its Chinese partners. , ... most recent trip to China having completed the negotiations and ... has also received an initial order of 120 Agro-Jet(R) for ...
... Efficacy Rates in Patients with Challenging Anatomy Consistent ... May 21 New data presented today at ... that Abbott,s market-leading XIENCE V(R) Everolimus Eluting Coronary ... (target lesion revascularization), stent thrombosis and major adverse ...
... sprees to boost emotional well-being in hard times , , ... worries, some women may actually overspend to try to cheer ... 700 women found that 79 percent said they,d go on ... 40 percent listed "depression" and 60 percent listed "feeling a ...
Cached Medicine News:Health News:Blood tests and better communication skills could cut over-prescribing of antibiotics 2Health News:Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association 2Health News:Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association 3Health News:Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association 4Health News:New Clinical Data Shows Significant Improvement in the Appearance of Fat Using SlimLipo(TM) Laser 2Health News:New Clinical Data Shows Significant Improvement in the Appearance of Fat Using SlimLipo(TM) Laser 3Health News:New Clinical Data Shows Significant Improvement in the Appearance of Fat Using SlimLipo(TM) Laser 4Health News:MIT is pleased to announce that it has signed the Joint Venture agreement with its Chinese partners and has received an initial order of 120 units for Animal vaccination 2Health News:Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study 2Health News:Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study 3Health News:Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study 4Health News:Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study 5Health News:Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study 6Health News:Shop 'Til You Drop: You May Feel Better 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: